New application of dihydroquercetin in prevention and treatment of arsenic trioxide induced cardiotoxicity
By using dihydroquercetin to inhibit the oxidative stress and apoptosis of myocardial and endothelial cells induced by arsenic trioxide, the problem of cardiotoxicity in the prior art is solved, and the safety of ATO is significantly improved.
Patent Information
- Application Number
- CN202411021757.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-29
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-07-29
AI Technical Summary
The prior art lacks effective treatment of cardiotoxicity induced by arsenic trioxide, limiting its medication safety in clinical applications.
Using dihydroquercetin as the only active ingredient or one of the active ingredients can alleviate the decline in cell viability and apoptosis by inhibiting the oxidative stress, DNA damage and decreased mitochondrial membrane potential of cardiomyocytes and endothelial cells induced by arsenic trioxide. Improve the cell morphology of myocardial and endothelial cells and inhibit iron death by upregulating GPX4/xCT.
It significantly alleviates myocardial damage induced by arsenic trioxide, relieves the decline in cell viability of myocardial and endothelial cells, improves cell morphology, inhibits cell apoptosis and oxidative stress, and improves the safety of ATO medication.
Smart Images

Figure CN118903101A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medical technology, and in particular relates to a new use of dihydroquercetin for preventing and treating arsenic trioxide-induced cardiotoxicity. Background Art
[0002] Arsenic trioxide (ATO) can prolong the survival of patients with acute promyelocytic leukemia (APL), but its severe cardiac toxicity limits its clinical application. Research data show that among APL patients treated with ATO, the incidence of cardiac discomfort is about 51.6%, the incidence of abnormal heart rate is about 47.4%, the incidence of abnormal electrocardiogram is about 61.1%, and the incidence of abnormal myocardial enzymes is about 2.1%. Among patients aged 46-60 who received ATO treatment, the incidence of treatment-related cardiac events was the highest, reaching 84.2%. ATO can even cause severe arrhythmias, endangering the life of patients.
[0003] ATO can act on a variety of cardiac cells to cause cardiotoxicity, including affecting cardiac development, cardiac morphology, cardiac contraction and dilation, and other cardiovascular functions. ATO changes the integrity of cardiomyocyte mitochondria, the production of ROS, calcium overload, and cell apoptosis in a dose-dependent and time-dependent manner, thus producing cardiotoxicity. In addition, ATO can also cause severe endothelial dysfunction.
[0004] Currently, there is a lack of effective treatments for ATO-induced cardiotoxicity in clinical practice. There is an urgent need in the art for drugs that can prevent and treat arsenic trioxide-induced cardiotoxicity to improve the safety of arsenic trioxide use. Summary of the invention
[0005] In order to solve the problem that the prior art lacks effective treatment for ATO-induced cardiotoxicity, the present invention provides a new use of dihydroquercetin (taxifolin, TAX) for preventing and treating arsenic trioxide-induced cardiotoxicity.
[0006] The technical solution of the present invention:
[0007] Application of dihydroquercetin in the preparation of medicines for preventing and treating arsenic trioxide-induced cardiotoxicity.
[0008] Furthermore, the drug for preventing and treating arsenic trioxide-induced cardiotoxicity has dihydroquercetin as the only active ingredient or one of the active ingredients.
[0009] Furthermore, the content of dihydroquercetin in the drug for preventing and treating arsenic trioxide-induced cardiotoxicity is 0.1wt% to 99wt%.
[0010] Furthermore, the drug for preventing and treating arsenic trioxide-induced cardiotoxicity also includes pharmaceutically acceptable excipients and / or carriers.
[0011] Furthermore, the drug for preventing and treating arsenic trioxide-induced cardiotoxicity is in the form of a gastrointestinal tract administration dosage form.
[0012] Furthermore, the dosage forms for administration via the gastrointestinal tract include tablets, granules, capsules, solutions, dry suspensions, powders, sustained-release agents, effervescent agents, emulsions, suspensions, syrups, drops or chewable tablets.
[0013] Furthermore, the drug for preventing and treating arsenic trioxide-induced cardiotoxicity can alleviate the decrease in cell viability of cardiomyocytes and endothelial cells caused by arsenic trioxide, and improve the cell morphology of cardiomyocytes and endothelial cells.
[0014] Furthermore, drugs for preventing and treating arsenic trioxide-induced cardiotoxicity reduce myocardial damage by inhibiting arsenic trioxide-induced oxidative stress, DNA damage and decreased mitochondrial membrane potential in cardiomyocytes and endothelial cells.
[0015] Furthermore, drugs for preventing and treating arsenic trioxide-induced cardiotoxicity alleviate arsenic trioxide-induced apoptosis of cardiomyocytes and endothelial cells by inhibiting the activation of Bax / Bcl-2.
[0016] Furthermore, drugs for the prevention and treatment of arsenic trioxide-induced cardiotoxicity inhibit ferroptosis of cardiomyocytes and endothelial cells by upregulating GPX4 / xCT.
[0017] Beneficial effects of the present invention:
[0018] The present invention verifies through experiments that dihydroquercetin can alleviate the cardiotoxicity induced by ATO in multiple ways, including alleviating the decreased cell viability of cardiomyocytes (AC16) and endothelial cells (HUVECs) caused by ATO, and significantly improving the cell morphology of cardiomyocytes and endothelial cells; dihydroquercetin alleviates the apoptosis of cardiomyocytes and endothelial cells induced by ATO by inhibiting the activation of Bax / Bcl-2, and inhibits the ferroptosis of cardiomyocytes and endothelial cells by upregulating GPX4 / xCT; dihydroquercetin significantly alleviates oxidative stress damage by reducing the levels of reactive oxygen species (ROS) and malondialdehyde (MDA) in cardiomyocytes and endothelial cells, and increasing the activities of antioxidant enzymes glutathione (GSH) and superoxide dismutase (SOD), and can also reverse the DNA damage and decreased mitochondrial membrane potential induced by ATO.
[0019] The present invention creatively discovers that dihydroquercetin has an excellent effect in preventing and treating arsenic trioxide-induced cardiotoxicity, provides a new strategy for improving the drug safety of arsenic trioxide, and provides a new insertion point for preparing new drugs for preventing or treating arsenic trioxide-induced cardiotoxicity, which has very important clinical application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 The figure is a comparison of the AC16 cell viability of different treatment groups in Example 1, A is the control group and the ATO treatment group, B is the control group and the ATO+TAX treatment group, and C is the control group and the TAX treatment group;
[0021] Figure 2 It is a comparison chart of HUVECs cell viability in different treatment groups in Example 1, A is the control group and the ATO treatment group, B is the control group and the ATO+TAX treatment group, and C is the control group and the TAX treatment group;
[0022] Figure 3 Comparison of the morphology of AC16 cells in different treatment groups in Example 2, scale bar = 100 μm;
[0023] Figure 4 Comparison of HUVECs cell morphology in different treatment groups in Example 2, scale bar = 100 μm;
[0024] Figure 5 Representative fluorescence images of TUNEL staining of AC16 cells in different treatment groups in Example 3, scale bar = 50 μm;
[0025] Figure 6 Representative fluorescence images of TUNEL staining of HUVECs cells in different treatment groups in Example 3, scale bar = 50 μm;
[0026] Figure 7 This is a comparison chart of the number of TUNEL positive cells in AC16 cells in different treatment groups quantitatively analyzed in Example 3;
[0027] Figure 8 This is a comparison chart of the number of TUNEL positive cells in HUVECs cells in different treatment groups in quantitative analysis in Example 3;
[0028] Fig. 9 This is a comparison of the protein expression levels of Caspase-3, Bcl-2 and Bax in AC16 cells in different treatment groups in Example 4;
[0029] Fig.10 This is a comparison chart of the protein expression levels of Caspase-3, Bcl-2 and Bax in HUVECs cells in different treatment groups in Example 4;
[0030] Fig.11 This is a comparative diagram of immunoblotting quantitative analysis of Caspase3 / β-actin, Bcl-2 / β-actin and Bax / β-actin in AC16 cells of different treatment groups in Example 4;
[0031] Fig.12 This is a comparative diagram of immunoblotting quantitative analysis of Caspase3 / β-actin, Bcl-2 / β-actin and Bax / β-actin in HUVECs cells in different treatment groups in Example 4;
[0032] Fig.13 This is a comparison of the protein expression levels of xCT and GPX4 in AC16 cells in different treatment groups in Example 5;
[0033] Fig.14 This is a comparison of the protein expression levels of xCT and GPX4 in HUVECs cells in different treatment groups in Example 5;
[0034] Fig.15 This is a comparative diagram of the immunoblot quantitative analysis of xCT / β-actin and GPX4 / β-actin in AC16 cells of different treatment groups in Example 5;
[0035] Fig.16 This is a comparative diagram of the quantitative analysis of xCT / β-actin and GPX4 / β-actin in HUVECs cells of different treatment groups in Example 5;
[0036] Fig.17 This is a comparison of the levels of MDA, GSH and SOD in AC16 cells in different treatment groups in Example 6;
[0037] Fig.18 This is a comparison of the levels of MDA, GSH and SOD in HUVECs cells in different treatment groups in Example 6;
[0038] Fig.19 Representative fluorescence images of ROS staining in AC16 cells and HUVECs cells in different treatment groups in Example 6;
[0039] Fig. 20 This is a comparison of the fluorescence intensity of ROS in AC16 cells in different treatment groups in Example 6;
[0040] Fig.21 This is a comparison of the fluorescence intensity of ROS in HUVECs cells in different treatment groups in Example 6;
[0041] Fig. 22Representative immunofluorescence images of H2AX staining of AC16 cells in different treatment groups in Example 7, scale bar = 50 μm, red represents H2AX, and blue represents cell nuclei;
[0042] Fig.23 Representative immunofluorescence images of H2AX staining of HUVECs cells in different treatment groups in Example 7, scale bar = 50 μm, red represents H2AX, and blue represents cell nuclei;
[0043] Fig.24 This is a comparison diagram of the quantitative analysis of H2AX fluorescence staining in AC16 cells in different treatment groups in Example 7;
[0044] Fig.25 This is a comparison diagram of the quantitative analysis of H2AX fluorescence staining in HUVECs cells in different treatment groups in Example 7;
[0045] Fig.26 Representative fluorescence images of JC-1 staining of AC16 cells in different treatment groups in Example 8, scale bar = 50 μm;
[0046] Fig. 27 Representative fluorescence images of JC-1 staining of HUVECs cells in different treatment groups in Example 8, scale bar = 50 μm;
[0047] Fig.28 This is a comparison chart of relative fluorescence values of quantitative analysis of JC-1 staining in AC16 cells of different treatment groups in Example 8;
[0048] Fig.29 This is a comparison chart of relative fluorescence values of the quantitative analysis of JC-1 staining in HUVECs cells in different treatment groups in Example 8. DETAILED DESCRIPTION
[0049] The technical solution of the present invention is further described below in conjunction with the embodiments, but it is not limited thereto. Any modification or equivalent replacement of the technical solution of the present invention without departing from the spirit and scope of the technical solution of the present invention shall be included in the protection scope of the present invention. The process equipment or devices not specifically noted in the following embodiments are all conventional equipment or devices in the art. If not specifically specified, the raw materials used in the embodiments of the present invention can be obtained commercially; if not specifically specified, the technical means used in the embodiments of the present invention are all conventional means well known to those skilled in the art.
[0050] Sources of chemicals and reagents used in the examples of the present invention:
[0051] Arsenic trioxide (ATO) was purchased from Heilongjiang Harbin Medical University Pharmaceutical Co., Ltd. Sodium arsenite chloride injection with a concentration of 1 mg / mL.
[0052] Dihydroquercetin (TAX) (purity 99.97%) was purchased from MedChemExpress (MCE) (Monmouth Junction, NJ, USA).
[0053] MDA, GSH and SOD kits were purchased from Jiancheng Bioengineering Institute (Nanjing).
[0054] CCK-8 kit, ROS fluorescence detection kit, TUNEL detection kit and JC-1 mitochondrial membrane potential detection kit were purchased from Beyotime (Shanghai).
[0055] The cardiomyocytes (AC16) and human umbilical vein endothelial cells (HUVECs) used in this example were from the Myocardial Ischemia Laboratory of Harbin Medical University, China.
[0056] All data in this example are expressed as mean ± SD. All data were statistically analyzed and plotted using GraphPad Prism software version 9.0 (GraphPad Software, Inc., CA, USA). Unpaired t-test was used for comparison between two groups, and one-way analysis of variance (ANOVA) was used for comparison between multiple groups. P < 0.05 was considered statistically significant between groups.
[0057] Example 1
[0058] This example investigates the ability of dihydroquercetin TAX to improve the decreased cell viability caused by ATO.
[0059] AC16 cells and HUVECs cells were cultured in high-glucose DMEM supplemented with 10% fetal bovine serum and 1% penicillin / streptomycin (v / v). The incubator temperature was set at 37°C and provided with 95% air and 5% carbon dioxide.
[0060] To determine the cytotoxicity of ATO and TAX on AC16 cells and HUVECs cells, CCK-8 assay was used to detect cell viability. According to the kit instructions, 5000 cells in each 100 μL cell suspension were seeded into 96-well culture plates.
[0061] AC16 cells were randomly divided into different groups:
[0062] (a) Control group: culture medium treatment for 24 h;
[0063] (b) TAX group: treated with 25, 50, 100, and 200 μM TAX for 24 h;
[0064] (c) ATO group: treated with 1.58, 3.16, 6.32, 9.46, 12.64, and 15.8 μM ATO for 24 h, respectively;
[0065] (d) ATO+TAX group: cells were pretreated with 25, 50, 100 and 200 μM TAX for 12 h, respectively, and then incubated with 5 μM ATO for 24 h.
[0066] HUVECs cells were randomly divided into different groups:
[0067] (e) Control group: culture medium treatment for 24 h;
[0068] (f) TAX group: treated with 25, 50, 100, and 200 μM TAX for 24 h;
[0069] (g) ATO group: treated with 1.58, 3.16, 6.32, 9.46, 12.64, and 15.8 μM ATO for 24 h, respectively;
[0070] (h) ATO+TAX group: cells were pretreated with 25, 50, 100 and 200 μM TAX for 12 h, respectively, and then incubated with 8 μM ATO for 24 h.
[0071] After treatment, incubate the cells with 10 μL of CCK-8 solution at 37°C for 1 h, and try to avoid light during the entire operation.
[0072] Avoid bubbles during operation, otherwise it will affect the optical density (OD).
[0073] The absorbance at 450 nm was measured using an ELISA reader (BioTek, Vermont, USA) to investigate the effects of ATO and TAX on the viability of AC16 and HUVECs cells. Figure 1 and Figure 2 The data in the figure are the mean ± SD of each group. *p<0.05, **p<0.01, ***p<0.001, n=3.
[0074] like Figure 1 -A and Figure 2 As shown in Figure 2A, after 24 h of ATO treatment, the cell viability of AC16 cells and HUVECs cells decreased in a dose-dependent manner, with IC50 values of 5.19 μM and 8.26 μM, respectively. Figure 1 -B and Figure 2 As shown in Figure 2-B, 50 μM TAX can significantly alleviate the decrease in HUVECs cell viability induced by ATO, but has no significant improvement on the cell viability of AC16 cells. However, 100 μM TAX can significantly improve the viability of AC16 cells. Figure 1 -C and Figure 2 As shown in Figure 5-C, when HUVECs and AC16 cells were treated with TAX at a concentration of 100 μM alone, there was no significant decrease in cell viability.
[0075] This indicates that ATO induces a decrease in the viability of AC16 cells and HUVECs in a dose-dependent manner. TAX improves the adverse effects of ATO on the viability of AC16 cells and HUVECs in a dose-dependent manner. TAX (25-200 μM) alone has no cytotoxic effect on AC16 cells and HUVECs.
[0076] Example 2
[0077] This example investigates the ability of dihydroquercetin TAX to improve cell morphological changes caused by ATO.
[0078] In this example, a bright-field inverted microscope was used to further observe the cell morphology of AC16 and HUVECs cells after exposure to ATO and TAX.
[0079] AC16 cells were randomly divided into different groups:
[0080] (a) Control group: culture medium treatment for 24 h;
[0081] (b) TAX group: 100 μM TAX treatment for 24 h;
[0082] (c) ATO group: 5 μM ATO treatment for 24 h;
[0083] (d) ATO+TAX group: pretreated with 100 μM TAX for 12 h, and then incubated with 5 μM ATO for 24 h.
[0084] HUVECs cells were randomly divided into different groups:
[0085] (e) Control group: culture medium treatment for 24 h;
[0086] (f) TAX group: treated with 100 μM TAX for 24 h;
[0087] (g) ATO group: treated with 8 μM ATO for 24 h;
[0088] (h) ATO+TAX group: pretreated with 100 μM TAX for 12 h, and then incubated with 8 μM ATO for 24 h.
[0089] The results are as follows Figure 3 and Figure 4 As shown in the figure, the AC16 and HUVECs cells in the TAX group alone did not change in cell morphology compared with the control group; however, when exposed to ATO, both cells underwent significant morphological changes, with the cells becoming smaller, deformed, and even wrinkled, rounded, and then falling off; after combined treatment with TAX, the cell morphology was significantly improved. This indicates that arsenic exposure can cause cell morphological changes, and TAX can improve the changes in cell morphology.
[0090] Example 3
[0091] This example investigates the ability of dihydroquercetin (TAX) to improve ATO-induced cell death.
[0092] Deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) is a method for detecting DNA fragmentation in cell death. In this example, the TUNEL kit was used to label the broken DNA fragments and then detect cell death. After TUNEL staining, the nuclear morphology of AC16 cells and HUVECs cells was detected to confirm the effect of ATO and TAX on cell death.
[0093] AC16 cells were randomly divided into different groups:
[0094] (a) Control group: culture medium treatment for 24 h;
[0095] (b) TAX group: 100 μM TAX treatment for 24 h;
[0096] (c) ATO group: 5 μM ATO treatment for 24 h;
[0097] (d) ATO+TAX group: pretreated with 100 μM TAX for 12 h, and then incubated with 5 μM ATO for 24 h.
[0098] HUVECs cells were randomly divided into different groups:
[0099] (e) Control group: culture medium treatment for 24 h;
[0100] (f) TAX group: treated with 100 μM TAX for 24 h;
[0101] (g) ATO group: treated with 8 μM ATO for 24 h;
[0102] (h) ATO+TAX group: pretreated with 100 μM TAX for 12 h, and then incubated with 8 μM ATO for 24 h.
[0103] After the cells were treated with drugs, they were washed twice with PBS, and then 100 μL of TUNEL detection solution was added. The cells were incubated at 37°C in the dark for 60 min, washed three times with PBS, stained with DAPI for 5 min, and observed under a fluorescence microscope.
[0104] Figure 5 and Figure 6 They are representative fluorescence images of TUNEL staining of AC16 cells and HUVECs cells in different treatment groups in this example; Figure 7 and Figure 8The figures are respectively the comparison of the number of TUNEL positive cells in AC16 cells and HUVECs cells in different treatment groups quantitatively analyzed in this example; the values are the mean ± SD of each group. *p<0.05, **p<0.01, ***p<0.001, n=3.
[0105] The results are as follows Figures 5 to 8 As shown in the figure, compared with the control group, the number of TUNEL-positive cells in the ATO group increased significantly (P<0.001), and a large number of apoptotic cells were found in the ATO-treated cells. Compared with the ATO group, the number of TUNEL-positive cells in the ATO+TAX group decreased significantly, showing a strong therapeutic effect (P<0.001orP<0.01). In addition, compared with the control group, the number of TUNEL-positive cells in the TAX group alone did not change. This indicates that ATO induces apoptosis, and TAX can alleviate ATO-induced cell death.
[0106] Example 4
[0107] This example investigates the ability of dihydroquercetin (TAX) to improve cell apoptosis induced by ATO exposure.
[0108] Cell apoptosis is an important process of ATO-induced cardiotoxicity, and ATO activates cell apoptosis through various mechanisms. In this example, Western blot was used to detect the expression levels of proteins related to the mitochondrial apoptosis pathway.
[0109] AC16 cells were randomly divided into different groups:
[0110] (a) Control group: culture medium treatment for 24 h;
[0111] (b) TAX group: 100 μM TAX treatment for 24 h;
[0112] (c) ATO group: 5 μM ATO treatment for 24 h;
[0113] (d) ATO+TAX group: pretreated with 100 μM TAX for 12 h, and then incubated with 5 μM ATO for 24 h.
[0114] HUVECs cells were randomly divided into different groups:
[0115] (e) Control group: culture medium treatment for 24 h;
[0116] (f) TAX group: treated with 100 μM TAX for 24 h;
[0117] (g) ATO group: treated with 8 μM ATO for 24 h;
[0118] (h) ATO+TAX group: pretreated with 100 μM TAX for 12 h, and then incubated with 8 μM ATO for 24 h.
[0119] AC16 cells and HUVECs cells in each treatment group were lysed in protease inhibitors and RIPA lysis buffer. After the protein concentration was determined by BCA kit, the protein samples were denatured in 5× loading buffer. The protein samples were added to 10% SDS-PAGE and then transferred to PVDF membranes. The membranes were blocked with 5% skim milk at room temperature for 1 h, and the membranes were incubated with the following primary antibodies at 4°C overnight: Bax (1:1000, abways), Bcl-2 (1:1000, abways), Caspase-3 (1:1000, abways) and β-actin (1:2000, Affinity Biosciences). After incubation with primary antibodies, the membranes were washed 3 times with PBST and incubated with the corresponding secondary antibodies (1:2000, Invitrogen) for 1 h. The PVDF membranes were scanned with a gel imaging system, and the protein bands were quantitatively analyzed using Image J software. β-actin was used as an internal reference.
[0120] Fig. 9 and Fig.10 These are the comparison diagrams of the protein expression levels of Caspase-3, Bcl-2 and Bax in AC16 cells and HUVECs cells in different treatment groups in this example; Fig.11 and Fig.12 These are the comparative diagrams of immunoblot quantitative analysis of Caspase3 / β-actin, Bcl-2 / β-actin and Bax / β-actin in AC16 cells and HUVECs cells in different treatment groups in this example; the values are the mean ± SD of each group. *p<0.05, **p<0.01, ***p<0.001, n>3.
[0121] The results are as follows Figures 9 to 12 As shown in the results, ATO significantly reduced the expression of anti-apoptotic protein Bcl-2 in AC16 and HUVECs cells (P<0.001), and upregulated the expression of pro-apoptotic proteins Bax and Caspase-3 (P<0.001). Compared with the ATO group, the expression of Bcl-2 in the ATO+TAX group was significantly upregulated (P<0.001), and the levels of Bax and Caspase-3 were significantly downregulated (P<0.001). This indicates that ATO activates cell apoptosis, while TAX can alleviate ATO-induced cell apoptosis.
[0122] Example 5
[0123] This example investigates the ability of dihydroquercetin (TAX) to improve ferroptosis induced by ATO exposure.
[0124] Ferroptosis is a non-apoptosis-dependent, non-necrotic form of cell death. Studies have shown that ferroptosis is associated with the occurrence and development of a variety of cardiovascular diseases, including drug-induced cardiotoxicity, myocardial ischemia / reperfusion injury, heart failure, heart transplantation, etc. In order to explore the role of ferroptosis in ATO-induced toxicity of different cardiac cells, this example used Western blot to determine the effect of ATO on the expression level of ferroptosis-related proteins in different cells.
[0125] AC16 cells were randomly divided into different groups:
[0126] (a) Control group: culture medium treatment for 24 h;
[0127] (b) TAX group: 100 μM TAX treatment for 24 h;
[0128] (c) ATO group: 5 μM ATO treatment for 24 h;
[0129] (d) ATO+TAX group: pretreated with 100 μM TAX for 12 h, and then incubated with 5 μM ATO for 24 h.
[0130] HUVECs cells were randomly divided into different groups:
[0131] (e) Control group: culture medium treatment for 24 h;
[0132] (f) TAX group: treated with 100 μM TAX for 24 h;
[0133] (g) ATO group: treated with 8 μM ATO for 24 h;
[0134] (h) ATO+TAX group: pretreated with 100 μM TAX for 12 h, and then incubated with 8 μM ATO for 24 h.
[0135] AC16 cells and HUVECs cells were lysed in protease inhibitors and RIPA lysis buffer. After the protein concentration was determined using a BCA kit, the protein samples were denatured in 5× loading buffer. The protein samples were added to 10% SDS-PAGE and then transferred to a PVDF membrane. The membrane was blocked with 5% skim milk at room temperature for 1 h, and the membrane was incubated with the following primary antibodies at 4°C overnight: GPX4 (1:1000, abways), xCT (1:1000, abways), and β-actin (1:2000, Affinity Biosciences). After incubation with the primary antibody, PBST was washed three times and the corresponding secondary antibody (1:2000, Invitrogen) was incubated for 1 h. The PVDF membrane was scanned using a gel imaging system, and the protein bands were quantitatively analyzed using Image J software. β-actin was used as an internal reference.
[0136] Fig.13 and Fig.14 These are comparison diagrams of the protein expression levels of xCT and GPX4 in AC16 cells and HUVECs cells in different treatment groups in this example; Fig.15 and Fig.16 These are the comparison diagrams of immunoblotting quantitative analysis of xCT / β-actin and GPX4 / β-actin in AC16 cells and HUVECs cells in different treatment groups in this example; the values are the mean ± SD of each group. *p<0.05, **p<0.01, ***p<0.001, n>3.
[0137] The results are as follows Figures 13 to 16 As shown in the figure, ATO significantly reduced the expression levels of GPX4 and xCT in AC16 and HUVECs cells (P<0.001orP<0.01). This indicates that ATO can cause ferroptosis in both cells. Compared with the ATO group, the expression levels of GPX4 and xCT in different cells in the ATO+TAX group were significantly increased (P<0.5orP<0.001). This indicates that ATO activates ferroptosis, and TAX can significantly alleviate ATO-induced ferroptosis.
[0138] Example 6
[0139] This example investigates the ability of dihydroquercetin (TAX) to improve oxidative stress damage caused by ATO exposure.
[0140] Arsenic-induced oxidative stress plays a central role in cardiac injury. GSH, SOD, MDA and ROS are closely related to oxidative stress response and can reflect the level of oxidative stress.
[0141] AC16 cells were randomly divided into different groups:
[0142] (a) Control group: culture medium treatment for 24 h;
[0143] (b) TAX group: 100 μM TAX treatment for 24 h;
[0144] (c) ATO group: 5 μM ATO treatment for 24 h;
[0145] (d) ATO+TAX group: pretreated with 100 μM TAX for 12 h, and then incubated with 5 μM ATO for 24 h.
[0146] HUVECs cells were randomly divided into different groups:
[0147] (e) Control group: culture medium treatment for 24 h;
[0148] (f) TAX group: treated with 100 μM TAX for 24 h;
[0149] (g) ATO group: treated with 8 μM ATO for 24 h;
[0150] (h) ATO+TAX group: pretreated with 100 μM TAX for 12 h, and then incubated with 8 μM ATO for 24 h.
[0151] In this example, the kit was used to measure the intracellular ROS, MDA, GSH and SOD levels by spectrophotometry. According to the kit instructions, the intracellular ROS level was detected using a reactive oxygen species detection kit, that is, the cells were washed with PBS after drug treatment, and then 10 μM DCFH-DA was added, incubated at 37°C in the dark for 30 minutes, and observed using a fluorescence microscope.
[0152] Fig.17 and Fig.18 These are comparison diagrams of MDA, GSH, and SOD levels in AC16 cells and HUVECs cells in different treatment groups in this example; Fig.19 Representative fluorescence images of ROS staining in AC16 cells and HUVECs cells in different treatment groups in Example 6; Fig. 20 and Fig.21 The figure is a comparison of the fluorescence intensity of ROS in AC16 cells in different treatment groups in this example; the values are the mean ± SD of each group. *p<0.05, **p<0.01, ***p<0.001, n=3.
[0153] The results are as follows Figures 17 to 21 As shown in the figure, compared with the control group, the MDA level in the two cells of the ATO group was significantly increased (P<0.001), and the GSH and SOD levels were significantly decreased (P<0.001). Compared with the ATO group, the combined group can significantly reduce the MDA level (P<0.001) and increase the activity of GSH and SOD (P<0.001orP<0.01). At the same time, the intracellular ROS level was evaluated by fluorescence staining, and the intensity of the green fluorescence image represented the level of ROS. Compared with the control group, the cells in the ATO group showed obvious green fluorescence, and the fluorescence area was larger and brighter, that is, the ROS level was significantly increased (P<0.001). TAX can significantly weaken the fluorescence intensity, indicating that the ROS level is reduced (P<0.001). The above results show that TAX can alleviate ATO-induced oxidative stress damage by reducing the levels of ROS and MDA and upregulating the activity of GSH and SOD.
[0154] Example 7
[0155] This example investigates the ability of dihydroquercetin TAX to improve DNA damage caused by ATO exposure.
[0156] As a clastogenic compound, ATO can induce DNA damage or mutation, mitotic arrest and apoptosis by changing mitochondrial membrane potential. γ-H2AX is a marker of DNA double-strand breaks in myocardium. Therefore, this example uses immunofluorescence analysis to evaluate DNA damage.
[0157] AC16 cells were randomly divided into different groups:
[0158] (a) Control group: culture medium treatment for 24 h;
[0159] (b) TAX group: 100 μM TAX treatment for 24 h;
[0160] (c) ATO group: 5 μM ATO treatment for 24 h;
[0161] (d) ATO+TAX group: pretreated with 100 μM TAX for 12 h, and then incubated with 5 μM ATO for 24 h.
[0162] HUVECs cells were randomly divided into different groups:
[0163] (e) Control group: culture medium treatment for 24 h;
[0164] (f) TAX group: treated with 100 μM TAX for 24 h;
[0165] (g) ATO group: treated with 8 μM ATO for 24 h;
[0166] (h) ATO+TAX group: pretreated with 100 μM TAX for 12 h, and then incubated with 8 μM ATO for 24 h.
[0167] Immunofluorescence analysis was used to detect the expression of intracellular DNA damage marker γ-H2AX. After drug treatment, cells were washed with 37°C PBS for 1 min, fixed with 4% formaldehyde solution for 10 min, permeabilized with 0.1% Triton X-100 for 10 min, and blocked with goat serum for 1 h. Subsequently, cells were incubated with γ-H2AX primary antibody (1:200, a11097, ABclonal, USA) at 4°C for 12 h. After washing with PBST, cells were incubated with Alexa Fluor 647-labeled goat anti-rabbit IgG secondary antibody (1:200, A0468) at room temperature for 1 h, and cells were stained with DAPI to mark the cell nucleus. Images were acquired using a fluorescence microscope.
[0168] Fig. 22 and Fig.23 Representative immunofluorescence images of H2AX staining of AC16 cells and HUVECs cells in different treatment groups in this example, scale bar = 50 μm, red represents H2AX, and blue represents cell nuclei; Fig.24 and Fig.25 This is a quantitative analysis comparison of H2AX fluorescence staining in AC16 cells and HUVECs cells in different treatment groups in this example; the values are the mean ± SD of each group. *p<0.05, **p<0.01, ***p<0.001, n=3.
[0169] The results are as follows Figure 22 to Figure 25 As shown in the figure, compared with the control group, ATO significantly enhanced the expression of H2AX in AC16 and HUVECs cells (P<0.001). Compared with ATO, the ATO+TAX group significantly reduced the expression of H2AX (P<0.01). This indicates that ATO significantly increases H2AX expression and TAX can inhibit ATO-induced DNA damage.
[0170] Example 8
[0171] This example investigates the ability of dihydroquercetin (TAX) to improve mitochondrial membrane dysfunction caused by ATO exposure.
[0172] Mitochondrial membrane potential (MMP) is a sensitive parameter for detecting mitochondrial dysfunction, and the maintenance of MMP is crucial for cell survival. In this example, a mitochondrial membrane potential detection kit (JC-1) was used to detect MMP.
[0173] AC16 cells were randomly divided into different groups:
[0174] (a) Control group: culture medium treatment for 24 h;
[0175] (b) TAX group: 100 μM TAX treatment for 24 h;
[0176] (c) ATO group: 5 μM ATO treatment for 24 h;
[0177] (d) ATO+TAX group: pretreated with 100 μM TAX for 12 h, and then incubated with 5 μM ATO for 24 h.
[0178] HUVECs cells were randomly divided into different groups:
[0179] (e) Control group: culture medium treatment for 24 h;
[0180] (f) TAX group: treated with 100 μM TAX for 24 h;
[0181] (g) ATO group: treated with 8 μM ATO for 24 h;
[0182] (h) ATO+TAX group: pretreated with 100 μM TAX for 12 h, and then incubated with 8 μM ATO for 24 h.
[0183] After the cells were treated with drugs, they were washed twice with PBS, then incubated with JC-1 working solution at 37°C in the dark for 30 min, washed twice with JC-1 buffer, and photographed using a fluorescence microscope. A decrease in the relative fluorescence (red / green fluorescence intensity ratio) level indicates a decrease in MMP.
[0184] Fig.26 and Fig. 27 Representative fluorescence images of AC16 cells and HUVECs cells stained with JC-1 in different treatment groups in this example, scale bar = 50 μm; Fig.28 and Fig.29 The figures are the comparison of relative fluorescence values of quantitative analysis of JC-1 staining in AC16 cells and HUVECs cells in different treatment groups in this example; the values are the mean ± SD of each group. *p<0.05, **p<0.01, ***p<0.001, n=3.
[0185] The results are as follows Figure 26 to Figure 29 As shown in the figure, compared with the control group, the ATO group significantly reduced the red / green fluorescence intensity ratio in AC16 and HUVECs cells (P<0.001), indicating that ATO significantly reduced MMP; and after TAX pretreatment, the ATO-induced MMP reduction was significantly alleviated (P<0.001orP<0.05). This shows that ATO significantly reduced MMP, and TAX can alleviate the ATO-induced MMP reduction.
Claims
1. Application of dihydroquercetin in the preparation of drugs for preventing and treating arsenic trioxide-induced cardiotoxicity.
2. The use of dihydroquercetin according to claim 1 in the preparation of a drug for preventing and treating arsenic trioxide-induced cardiotoxicity, characterized in that: The drug for preventing and treating arsenic trioxide-induced cardiotoxicity uses dihydroquercetin as the only active ingredient or one of the active ingredients.
3. Use of dihydroquercetin according to claim 1 or 2 in the preparation of a drug for preventing and treating arsenic trioxide-induced cardiotoxicity, characterized in that: The content of dihydroquercetin in the drug for preventing and treating arsenic trioxide-induced cardiotoxicity is 0.1 wt% to 99 wt%.
4. The use of dihydroquercetin according to claim 3 in the preparation of a drug for preventing and treating arsenic trioxide-induced cardiotoxicity, characterized in that: The drug for preventing and treating arsenic trioxide-induced cardiotoxicity also includes pharmaceutically acceptable adjuvants and / or carriers.
5. The use of dihydroquercetin according to claim 4 in the preparation of a drug for preventing and treating arsenic trioxide-induced cardiotoxicity, characterized in that: The drug for preventing and treating arsenic trioxide-induced cardiotoxicity is in the form of a gastrointestinal tract administration dosage form.
6. The use of dihydroquercetin in the preparation of a drug for preventing and treating arsenic trioxide-induced cardiotoxicity according to claim 5, characterized in that: The dosage forms for administration via the gastrointestinal tract include tablets, granules, capsules, solutions, dry suspensions, powders, sustained-release agents, effervescent agents, emulsions, suspensions, syrups, drops or chewable tablets.
7. The use of dihydroquercetin according to claim 6 in the preparation of a drug for preventing and treating arsenic trioxide-induced cardiotoxicity, characterized in that: The drug for preventing and treating arsenic trioxide-induced cardiotoxicity can alleviate the decrease in cell viability of myocardial cells and endothelial cells caused by arsenic trioxide, and improve the cell morphology of myocardial cells and endothelial cells.
8. The use of dihydroquercetin according to claim 7 in the preparation of a drug for preventing and treating arsenic trioxide-induced cardiotoxicity, characterized in that: Drugs for preventing and treating arsenic trioxide-induced cardiotoxicity reduce myocardial damage by inhibiting arsenic trioxide-induced oxidative stress, DNA damage, and decreased mitochondrial membrane potential in cardiomyocytes and endothelial cells.
9. The use of dihydroquercetin according to claim 8 in the preparation of a drug for preventing and treating arsenic trioxide-induced cardiotoxicity, characterized in that: Drugs for the prevention and treatment of arsenic trioxide-induced cardiotoxicity alleviate arsenic trioxide-induced apoptosis of cardiomyocytes and endothelial cells by inhibiting the activation of Bax / Bcl-2.
10. Use of dihydroquercetin according to claim 9 in the preparation of a drug for preventing and treating arsenic trioxide-induced cardiotoxicity, characterized in that: Drugs that prevent and treat arsenic trioxide-induced cardiotoxicity inhibit ferroptosis in cardiomyocytes and endothelial cells by upregulating GPX4 / xCT.
Citation Information
Patent Citations
Method of using nutritional compounds dihydroquercetin (taxifolin) and arabinogalactan in combination with dihydroquercetin (taxifolin) to reduce and control cardiometabolic risk factors associated with metabolic syndrome and hypercholesterolemia
CN105263340A
Applications of dihydroquercetin in preparing medicines for protecting drug-induced acute liver injury
CN108653267A
Application of dihydroquercetin in preparation of medicine for treating ferroptosis
CN115531372A
Application of TRIM26 in preparation of NASH biomarker and medicine
CN116121362A
A pharmaceutical composition containing dihydroquercetin, drone brood, and vitamin D3, used for the prevention and treatment of cardiovascular pathologies.
RU2021132757A
